Volume 3 Supplement 2
Platelet activating factor-induced mast cell degranulation is inhibited by rupatadine, and to a lower extent by levocetirizine and desoratadine, in a mast cell line (LAD-2)
© Mullol et al; licensee BioMed Central Ltd. 2013
Published: 16 July 2013
Platelet activating factor (PAF) is a lipid mediator that appears to be involved in the pathophysiology of several allergic reactions such as anaphylaxis and potentially urticaria and allergic rhinitis. The role of rupatadine, a drug with dual antihistamine and anti-PAF effect, in mast cell (MC) degranulation is not known. The objective of this study was to investigate the expression of PAF receptors and the effect of rupatadine on PAF-induced MC degranulation compared with other second generation antihistamines (desloratadine, levocetizine) and a pure specific PAF inhibitor in a human mast cell line (LAD-2).
MC degranulation was evaluated by the â-hexosaminidase and histamine release while PAF receptor expression was evaluated by western blot. After stimulation with PAF in a dose-response and time course manner, the optimal PAF conditions to induce LAD-2 degranulation were identified (10 µM and 30 minutes). The effects of rupatadine, desloratadine, and levocetirizine (from 1µM to 100 µM) on PAF-induced LAD-2 degranulation were investigated. The inhibitory effect of CV6209 (specific anti-PAF) at 2 µM was used as positive control in all experiments.
Protein expression of the PAF receptor was found in LAD-2 cells. Rupatadine (5 to 10 µM, p<0.005) and levocetirizine (5 µM, p<0.01) but not desloratadine inhibited PAF-induced â-hexosaminidase release. Rupatadine (1 to 10 µM, p<0.01), levocetirizine (1 to 25 µM, p<0.05), and desloratadine (10 µM, p<0.05) also inhibited PAF-induced histamine release.
This study shows that the ant-H1 compunds rupatadine, and to a lower extent levocetirizine and desloratadine, have an anti-PAF effect in the mast cell line LAD-2, suggesting that rupatadine could be more effective than other antihistamine drugs in those allergic disorders where PAF may act as an important inflammatory mediator.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.